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Abstract 52 
Merozoites of the protozoan parasite responsible for the most virulent form 53 
of malaria, Plasmodium falciparum, invade erythrocytes. Invasion involves 54 
discharge of rhoptries, specialized secretory organelles. Once intracellular, 55 
parasites induce increased nutrient uptake by generating new permeability 56 
pathways (NPP) including a Plasmodium surface anion channel (PSAC). 57 
RhopH1/Clag3, one member of the three-protein RhopH complex, is 58 
important for PSAC/NPP activity. However, the roles of the other members 59 
of the RhopH complex in PSAC/NPP establishment are unknown and it is 60 
unclear whether any of the RhopH proteins play a role in invasion. Here we 61 
demonstrate that RhopH3, the smallest component of the complex, is 62 
essential for parasite survival. Conditional truncation of RhopH3 63 
substantially reduces invasive capacity. Those mutant parasites that do 64 
invade are defective in nutrient import and die. Our results identify a dual 65 
role for RhopH3 that links erythrocyte invasion to formation of the 66 
PSAC/NPP essential for parasite survival within host erythrocytes. 67 
 68 
69 
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Introduction 70 
Parasites of the genus Plasmodium are the causative agents of malaria, a 71 
disease that claims nearly 600,000 lives each year (1). Of the five 72 
Plasmodium species that infect humans, Plasmodium falciparum is 73 
responsible for nearly all the mortality associated with malaria. The disease 74 
is the result of asexual replication of the parasite in erythrocytes. For 75 
approximately the first half of the 48 h P. falciparum intraerythrocytic life 76 
cycle, the parasite exists in a mononuclear trophozoite form (the earliest 77 
stages of which are generally referred to as ring stages), during which the 78 
parasite grows rapidly. During this phase, P. falciparum-infected 79 
erythrocytes gain the capacity to adhere to host vascular endothelium, a 80 
process that depends on the export of parasite proteins to form adhesive 81 
structures called knobs at the host erythrocyte surface. Nuclear division 82 
then commences, initiating differentiation into a schizont (a process called 83 
schizogony). This multinucleated form eventually undergoes segmentation 84 
to form invasive merozoites that egress upon rupture of the infected 85 
erythrocyte to invade new erythrocytes.  86 
Egress and erythrocyte invasion involves the regulated discharge of 87 
several sets of apical merozoite secretory organelles that are unique to 88 
apicomplexan parasites. The largest of these organelles, called rhoptries, 89 
contain several proteins involved in adhesion to the host cell. Rhoptries are 90 
also thought to mediate formation of the nascent parasitophorous vacuole 91 
(PV), a membranous compartment that surrounds the parasite after entry 92 
has been completed (2,3). Despite the importance of rhoptries in invasion 93 
and subsequent host cell remodeling, a detailed understanding of the 94 
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function of many rhoptry proteins is lacking. Rhoptries comprise at least two 95 
subdomains(3) referred to as the rhoptry neck and the bulb. The contents of 96 
these subdomains likely mediate different functions, as reflected by 97 
evidence suggesting that they are released sequentially during invasion (4). 98 
Proteins of the rhoptry neck are well conserved between Plasmodium spp. 99 
and the related apicomplexan parasite Toxoplasma gondii, suggesting 100 
conserved functions (3,5). In contrast, proteins of the rhoptry bulb appear 101 
to be genus-specific, perhaps reflecting functions unique to each parasite 102 
(3). A function for several Plasmodium rhoptry bulb proteins has been 103 
proposed, such as a role for a protein called RAMA in transport of proteins 104 
to the rhoptry (6), but the inability to produce mutants lacking these 105 
proteins has precluded conclusive assignments of function (7). Hence, the 106 
molecular functions of most rhoptry proteins remain unknown.   107 
 One component of the P. falciparum rhoptry bulb that has received 108 
particular attention is the so-called high molecular weight (HMW) rhoptry or 109 
RhopH complex, which consists of three proteins called RhopH1/Clag, 110 
RhopH2, and RhopH3 (8,9). Whilst RhopH2 and RhopH3 are each encoded by 111 
single-copy genes, RhopH1/Clag, the largest component of the complex, 112 
exists in 5 isotypes encoded by separate genes entitled clag2, clag3.1, 113 
clag3.2, clag8 and clag9 (10,11). RhopH1/Clag3.1 and RhopH1/Clag3.2 are 114 
nearly identical proteins that are expressed in a mutually exclusive manner 115 
(12-14). Each RhopH complex contains only one form of RhopH1/Clag (11), 116 
so each parasite has the potential to produce four different RhopH 117 
complexes, differentiated by the particular RhopH1/Clag isotype bound. All 118 
members of the RhopH complex are expressed late in the intraerythrocytic 119 
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cycle (8). The complex is then released during invasion (15) and inserted 120 
into the nascent PV membrane (PVM) soon after parasite entry (16,17).  121 
Genetic and chemical genetic investigation has revealed a role for 122 
the RhopH1/Clag3 proteins in the function of the Plasmodium surface anion 123 
channel (PSAC), a new permeability pathway (NPP) induced in host 124 
erythrocytes following parasite entry and involved in nutrient acquisition by 125 
the intracellular parasite (18). Pharmacological inhibition of 126 
RhopH1/Clag3.2 function was found to block PSAC/NPP activity, and 127 
selection for drug-resistant mutants revealed that part of the protein is 128 
exposed at the surface of the erythrocyte and that it may form the channel 129 
itself (19,20). However, parasites that do not produce either 130 
RhopH1/Clag3.1 or RhopH1/Clag3.2 display only a small growth 131 
disadvantage (13) and inhibition of the function of these proteins has only a 132 
small effect on parasite growth rates in vitro (21). Parasites lacking 133 
RhopH1/Clag9 are viable, and an early report suggested that loss of the 134 
clag9 gene resulted in loss of binding to CD36 (22). However, this has been 135 
disputed (23), as a subsequent study identified another gene closely linked 136 
to the clag9 gene that is important for CD36 binding (24). Hence, whilst the 137 
function of RhopH1/Clag9 remains to be determined, like RhopH1/Clag3.1 138 
and RhopH1/Clag 3.2, it is not essential. There are no reports describing a 139 
deletion, or attempted deletion, of clag2 or clag8. 140 
Much less is known of the function of the RhopH2 and RhopH3 141 
components of the complex. There is no report of attempted disruption of 142 
the rhopH2 gene, but the rhopH3 gene is refractory to deletion in the 143 
haploid blood stages (25), suggesting an essential role. Hints that this might 144 
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include a function in invasion derive from studies showing that antibodies to 145 
RhopH3 can inhibit invasion (8,26). However, whether RhopH3 plays other 146 
essential roles that involve all forms of the RhopH complex is unknown.   147 
 Here we use a conditional mutagenesis approach to modify the 148 
rhopH3 gene in a manner that blocks formation of the RhopH complex. The 149 
resulting mutant parasites show two distinct phenotypes: a significant 150 
decrease in the level of erythrocyte invasion and a complete block in 151 
intracellular development at the trophozoite stage. Our findings reveal that 152 
RhopH3 and the RhopH complex have essential roles in two distinct stages of 153 
the erythrocytic lifecycle. 154 
 155 
Results 156 
Efficient conditional truncation of the rhopH3 gene. Previous attempts to 157 
disrupt the P. falciparum rhopH3 gene using conventional genetic 158 
techniques were unsuccessful (25), suggesting an indispensable role in 159 
asexual blood stages. To gain insights into this role we therefore adopted 160 
the DiCre conditional recombinase system recently adapted to P. falciparum 161 
(27) to examine the consequences of functional inactivation of RhopH3. For 162 
this, we used Cas9-mediated genome editing (28) to introduce synthetic 163 
introns containing loxP sites (29) into the rhopH3 gene such that they 164 
flanked an internal region spanning exons 4-6, the region of the gene that 165 
shows the highest level of conservation across Plasmodium rhopH3 orthologs 166 
(Figure 1A, Figure 1 – figure supplement 1). This genomic modification was 167 
made in the DiCre-expressing P. falciparum 1G5DC parasite clone (27) in 168 
order that excision of the floxed sequence could be induced by treatment of 169 
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the transgenic parasites with rapamycin. DiCre-mediated excision was 170 
predicted to generate an internally-truncated mutant form of rhopH3 171 
lacking its most highly conserved region. 172 
 Successful modification of the rhopH3 gene in the transfected 173 
parasite population following introduction of the targeting vector was 174 
confirmed by diagnostic PCR (not shown). Subsequent limiting dilution 175 
cloning of the modified parasites resulted in the isolation of parasite clones 176 
rhopH3-loxP 5F5 and rhopH3-loxP 4B11, which were derived from 177 
independent transfections using different guide RNAs. Modification of the 178 
native rhopH3 locus in the expected fashion was confirmed in both parasite 179 
clones by diagnostic PCR and Southern blot (Figure 1B and Figure 1C). Both 180 
clones displayed RhopH3 expression levels and in vitro replication rates 181 
indistinguishable from the parental 1G5DC parasites (Figure 1 – figure 182 
supplement 2), indicating that the modified rhopH3 gene generated wild 183 
type levels of RhopH3 and that the modifications had no impact on parasite 184 
viability. The clones were therefore used for all subsequent experiments.  185 
 To examine the efficiency of conditional excision of the floxed 186 
sequence in the rhopH3-loxP clones, tightly synchronized ring stage cultures 187 
of both clones were divided into two and treated for 4 h with either 188 
rapamycin or DMSO (vehicle control). Following washing and further 189 
incubation for ~44 h to allow maturation of the parasites to schizont stage 190 
(at which peak expression of RhopH3 occurs (8)), genomic DNA from the 191 
clones was examined by PCR and Southern blot. This revealed highly 192 
efficient excision of the floxed rhopH3 sequence (Figure 1D and Figure 1E).  193 
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DiCre-mediated site-specific recombination between the introduced 194 
loxP sites in the modified rhopH3 locus of the rhopH3-loxP parasites was 195 
expected to reconstitute a functional, albeit chimeric, intron. Upon splicing 196 
of this intron exons 3 and 7 are placed in frame, producing a modified 197 
RhopH3 gene product (called RhopH3Δ4-6) that retains wild type N-terminal 198 
and C-terminal segments but lacking residues encoded by exons 4-6. 199 
Extracts of the rapamycin-treated and control parasites were analyzed by 200 
immunoblot ~44 h following treatment using antibody anti-Ag-44, which 201 
recognizes an epitope within the C-terminal segment of RhopH3 encoded by 202 
exon 7 (30). As shown in Figure 1F and Figure 1 – figure supplement 3, 203 
rapamycin treatment produced the expected change in mass, converting the 204 
~110 kDa wild-type RhopH3 to a ~70 kDa RhopH3Δ4-6 product. This 205 
conversion was highly efficient, with no residual full-length protein 206 
detected in the rapamycin-treated schizonts. These results confirmed the 207 
excision data and demonstrated essentially complete conditional truncation 208 
of RhopH3 within a single erythrocytic cycle in the rhopH3-loxP parasite 209 
clones.  210 
 211 
Truncation of rhopH3 leads to mislocalization of other components of the 212 
RhopH complex. We next aimed to determine the effects of RhopH3 213 
truncation on its subcellular localization within the parasite, as well as on 214 
the trafficking of other members of the RhopH complex. 215 
Immunofluorescence analysis (IFA) showed that, as expected, RhopH3 216 
colocalized with the rhoptry marker RAP2 (31,32) in mature schizonts of 217 
control rhopH3-loxP parasites (Figure 2A). However, in rapamycin-treated 218 
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(RhopH3Δ4-6) parasites, this colocalization was lost, although RAP2 was still 219 
detected in a punctate, apically-disposed pattern typical of rhoptries 220 
(Figure 2A). To determine the effects of this mistrafficking on localization of 221 
the other two RhopH complex proteins, control and rapamycin-treated 222 
rhopH3-loxP parasites were probed with anti-RAP2 as well as either anti-223 
RhopH1/Clag3.1 (11) or anti-RhopH2 antibodies (9). This showed that, as in 224 
the case of RhopH3, rhoptry localization of both RhopH1/Clag3.1 and 225 
RhopH2 was lost in rapamycin-treated parasites (Figure 2A). These results 226 
indicated that truncation of RhopH3 to the RhopH3Δ4-6 form resulted in 227 
mistrafficking of at least some components of the RhopH complex. To 228 
determine whether the mistrafficked rhoptry proteins all localized to the 229 
same parasite compartment, the parasites were co-stained with various 230 
combinations of antibodies against two of the three complex proteins. This 231 
showed that neither RhopH2 nor RhopH1/Clag3.1 colocalized with 232 
RhopH3Δ4-6 in the mutant parasites (Figure 2B). The RhopH2 and 233 
RhopH1/Clag3.1 signals were also distinct in the mutant parasites, although 234 
in this case some limited colocalization of these proteins was apparent 235 
(bottom images, Figure 2B).  236 
To better define the fate of the mistrafficked RhopH3Δ4-6 in the 237 
mutant parasites, rapamycin-treated mature schizonts were probed with 238 
antibodies to the merozoite plasma membrane surface marker MSP1. This 239 
indicated that the mutant protein was expressed in a location surrounding 240 
(and so likely external to) the plasma membrane of individual segmented 241 
intracellular merozoites (Figure 2 – figure supplement 1). In confirmation of 242 
this, IFA of naturally released free merozoites showed that the truncated 243 
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RhopH3Δ4-6 was often largely undetectable in merozoites of the mutant 244 
parasites (Figure 2C). 245 
One interpretation of these results was that truncation of RhopH3 246 
interfered with formation of the RhopH complex. To test this notion, we 247 
used a monoclonal antibody (mAb) specific for RhopH2 to 248 
immunoprecipitate the complex from extracts of schizonts of rhopH3-loxP 249 
clone 5F5. As shown in Figure 2D, both RhopH3 and RhopH1/Clag3.1 were 250 
precipitated as expected from lysates of control parasites. In contrast, 251 
RhopH3Δ4-6 was undetectable in the precipitate from lysates of rapamycin-252 
treated parasites, although RhopH1/Clag3.1 could still be detected. This 253 
showed that truncation of RhopH3 ablates its association with RhopH2, 254 
although it does not appear to affect the interaction between RhopH2 and 255 
RhopH1/Clag3.1. Collectively, these results suggested that truncation of 256 
RhopH3 caused mistrafficking of other components of the complex, probably 257 
due to loss of the association between RhopH3 and these other proteins.  258 
 259 
Loss of the RhopH complex is a lethal event. The above results showed 260 
that whilst truncation of RhopH3 affected trafficking of the RhopH complex, 261 
it did not prevent schizont development in the erythrocytic growth cycle in 262 
which the parasites were treated with rapamycin (henceforth referred to as 263 
cycle 1). To evaluate the effects of RhopH3 modification and mistrafficking 264 
on longer-term parasite viability, we first exploited a recently developed 265 
assay in which parasite replication is assessed in 96-well microplates over a 266 
period of 5-7 erythrocytic cycles by visualization of the localized lysis of 267 
host erythrocytes in static cultures in 96-well microplates. Under these 268 
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conditions, successful parasite growth results in formation of 269 
microscopically discernible zones of clearance of erythrocytes referred to as 270 
plaques (33). As shown in Table 1, in 3 separate assays DMSO-treated 271 
rhopH3-loxP parasites seeded at ~10 parasites per well produced plaques in 272 
nearly every well, with a mean average of ~8 plaques per well for clone 5F5 273 
and ~5 plaques per well for clone 4B11 (Table 1). In contrast, in the plates 274 
seeded with an identical density of rapamycin-treated parasites, only ~10% 275 
of the wells contained plaques and no well contained more than one plaque 276 
(Figure 3A, Table 1). Analysis by diagnostic PCR of several parasite clones 277 
isolated from individual plaques that appeared in plates seeded with 278 
rapamycin-treated parasites revealed that in all cases they derived from 279 
parasites that possessed an intact rhopH3-loxP gene, indicating that these 280 
corresponded to a small subpopulation of parasites in which excision of the 281 
floxed sequence had not taken place (Figure 3B). Further analysis by PCR of 282 
one of these non-excised clones showed that the DiCre cassette had been 283 
lost (Figure 3C) probably due to a genomic rearrangement. This parasite 284 
clone (named RhopH3 NE) served as a useful control for subsequent 285 
experiments.  286 
 To further examine the effects of RhopH3 truncation on long-term 287 
parasite viability, low parasitaemia cultures of the rhopH3-loxP clones 5F5 288 
and 4B11 were divided equally into two flasks, treated with either DMSO or 289 
rapamycin, then the parasites simply maintained in continuous culture, 290 
monitoring increase in parasitaemia at 48 h intervals as well taking samples 291 
for analysis by diagnostic PCR. Cultures of the parental 1G5DC parasites as 292 
well as the DiCre-defective RhopH3 NE clone were similarly treated and 293 
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monitored in parallel. As shown in Figure 3D, whilst replication of the 294 
1G5DC and RhopH3 NE parasites was unaffected by rapamycin treatment, 295 
the rapamycin-treated 5F5 and 4B11 clones showed a dramatic decrease in 296 
growth rate. However in both clones the appearance of replicating parasites 297 
was evident by cycle 3, suggesting that these might correspond to a minor 298 
population of normally-replicating non-excised parasites. Diagnostic PCR 299 
analysis of the 5F5 culture supported this notion. At the end of cycle 1, PCR 300 
using primers that distinguish between the excised and non-excised locus 301 
showed the expected highly efficient excision of the floxed rhopH3-loxP 302 
sequence in the rapamycin-treated culture, with the non-excised locus 303 
undetectable. However, periodic examination of the parasites by diagnostic 304 
PCR over the ensuing 6 erythrocytic cycles showed a time-dependent 305 
increase in the proportion of non-excised parasites in the rapamycin-treated 306 
culture, suggesting that the initially undetectable population of non-excised 307 
parasites gradually overgrew the cultures. This occurred likely as a result of 308 
a selective advantage conferred on them by the replication defect displayed 309 
by the RhopH3Δ4-6 parasites. By cycle 5, the excised locus was hardly 310 
detectable in the rapamycin-treated culture (Figure 3E). Together with the 311 
results of the plaque assay, these results allowed us to conclude that 312 
truncation of RhopH3 results in complete loss of long-term parasite viability. 313 
 314 
Loss of the RhopH complex leads to an invasion defect. The severe growth 315 
defect displayed in the plaque and growth assays could result from an 316 
inability of mutant parasites to egress from the host erythrocyte, a block in 317 
invasion, or a developmental arrest during intracellular growth. We 318 
 13
therefore next investigated the capacity of RhopH3Δ4-6 parasites to undergo 319 
egress. For this, we used time-lapse differential interference contrast (DIC) 320 
microscopy to observe the egress of merozoites from highly mature, 321 
synchronized schizonts at the end of cycle 1 (i.e. ~45 h following treatment 322 
of ring-stage rhopH3-loxP parasites with rapamycin or DMSO). This revealed 323 
no gross differences in the efficiency or morphology of egress 324 
(Supplementary video 1), indicating that the absence of the RhopH complex 325 
from rhoptries does not affect egress.  326 
To investigate a potential invasion phenotype resulting from RhopH3 327 
truncation, a synchronized culture of rhopH3-loxP parasites at early ring 328 
stage was divided into two, treated with either DMSO or rapamycin and then 329 
allowed to mature to schizont stage before purifying the mature schizonts 330 
and adding them to fresh erythrocytes. After incubation for a further 4 h to 331 
allow the rhopH3-loxP schizonts to undergo merozoite egress and invasion, 332 
the percentage of erythrocytes infected with cycle 2 ring-stage parasites 333 
was quantified. The results consistently showed that the ring-stage 334 
parasitemia values in cultures derived from the rapamycin-treated rhopH3-335 
loxP parasites was only ~50% of that in their DMSO-treated counterparts 336 
(Figure 3F). Importantly, invasion by the control RhopH3 NE and the 337 
parental 1G5DC parasites was unaffected by rapamycin treatment. Taken 338 
together with the other results, these data showed that the absence of the 339 
RhopH complex from parasite rhoptries significantly affects the ability of 340 
the parasite to invade new host cells. 341 
 342 
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The RhopH complex is required for intracellular parasite development. 343 
Although the results of the above experiments pointed to a severe invasion 344 
defect in parasites lacking the RhopH complex, it was unclear whether this 345 
could be sufficient to explain the results of the plaque assay, which 346 
indicated a complete lack of long-term viability in the RhopH3Δ4-6 mutants. 347 
To explore this further, we examined growth and development of the 348 
mutants using microscopic examination of Giemsa-stained cultures. This 349 
showed that whereas rapamycin-treated rhopH3-loxP parasites appeared 350 
morphologically normal at the end of the cycle 1 as well as at the ring stage 351 
of cycle 2, development of the mutant parasites stalled at trophozoite stage 352 
in cycle 2 (Figure 4A) and the parasites did not develop into schizonts. To 353 
confirm this developmental block we used flow cytometry to monitor the 354 
DNA content of the parasites in cycle 2. This confirmed that rings derived 355 
from rapamycin-treated rhopH3-loxP parasites did not increase their DNA 356 
content during cycle 2 (Figure 4B), i.e. they did not progress to the 357 
multinuclear schizont stage. Taken together, these data indicated that the 358 
RhopH complex is essential for the trophozoite to schizont developmental 359 
transition of the intracellular parasite.  360 
 361 
Protein export occurs normally in the RhopH3Δ4-6 mutants. Export of 362 
parasite proteins into the host erythrocyte is important for parasite 363 
virulence and for the uptake of nutrients; blocking export prevents 364 
modification of the erythrocyte surface with the knob structures that play a 365 
role in cytoadhesion, and also prevents development of the parasite beyond 366 
the trophozoite stage (34,35). Since we observed a similar growth 367 
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phenotype in cycle 2 in the RhopH3Δ4-6 parasites, we decided to determine 368 
whether the developmental arrest was the result of a generalized defect in 369 
protein export. To do this, we examined the subcellular localization of 370 
KAHRP and MAHRP1, parasite proteins that are established markers for 371 
protein export and Maurer’s clefts (intraerythrocytic membranous structures 372 
of parasite origin) respectively, in cycle 2 trophozoites derived from 373 
rapamycin-treated rhopH3-loxP parasites (36,37). This revealed no 374 
discernible alterations in protein export and Maurer’s cleft formation in the 375 
RhopH3Δ4-6 mutants (Figure 5A). This conclusion was corroborated by 376 
electron microscopy, which revealed the formation of knobs on the surface 377 
of erythrocytes infected with rapamycin-treated rhopH3-loxP parasites 378 
(Figure 5B). We concluded that protein export from the intracellular 379 
parasite can take place normally in the absence of the RhopH complex. 380 
 381 
Import pathways are defective in rhopH3 mutant parasites. The 382 
developmental arrest observed in cycle 2 trophozoites of the RhopH3Δ4-6 383 
parasites was strikingly reminiscent of the effect of isoleucine starvation on 384 
P. falciparum (38) Isoleucine is transported into the parasitized cell via the 385 
PSAC/NPP, the parasite-induced uptake pathway responsible for enhanced 386 
nutrient uptake in parasite-infected erythrocytes (39). The PSAC/NPP is also 387 
responsible for the permeability of parasite-infected erythrocytes to the 388 
alcohol sugar sorbitol (18), leading to the capacity of sorbitol solutions to 389 
mediate osmotic lysis of infected erythrocytes. This lysis can be readily 390 
quantified by measuring levels of host cell hemoglobin released following 391 
treatment of parasitized cells with a sorbitol solution (40). To determine 392 
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whether the PSAC/NPP was functional in the RhopH3Δ4-6 mutants, their 393 
resistance to sorbitol-mediated lysis was assessed. As shown in Figure 6A, 394 
erythrocytes infected with parental 1G5DC parasites or the non-excised 395 
RhopH3 NE clone displayed the expected sensitivity to sorbitol, as did 396 
erythrocytes infected with control (DMSO-treated) rhopH3-loxP parasites. In 397 
contrast, erythrocytes infected with cycle 2 rapamycin-treated rhopH3-loxP 398 
parasites were insensitive to sorbitol; the amount of hemoglobin released 399 
upon sorbitol treatment was not significantly different from the amount 400 
released by treatment of the infected erythrocytes with an isotonic control 401 
buffer (PBS). 402 
To further investigate the activity of the PSAC/NPP in the RhopH3Δ4-403 
6 mutants, erythrocytes infected with cycle 2 rings were incubated with 5-404 
aminolevulinic acid (5-ALA). This compound is excluded from uninfected 405 
erythrocytes but is taken up by infected erythrocytes and converted to 406 
fluorescent protoporphyrin IX (PPIX) (41). Import of 5-ALA has previously 407 
been shown to be sensitive to furosemide, a small molecule inhibitor of 408 
PSAC/NPP, and is also blocked upon downregulation of parasite export and 409 
PSAC/NPP activity in transgenic P. falciparum (34,41,42). Import of 5-ALA 410 
therefore acts as a convenient reporter for PSAC/NPP activity. Examination 411 
by fluorescence microscopy (Figure 6B and 6C) and FACS (Figure 6D) showed 412 
that erythrocytes infected with DMSO-treated rhopH3-loxP clone 5F5 and 413 
4B11 parasites readily took up 5-ALA, whereas no fluorescence was observed 414 
in erythrocytes infected with rapamycin-treated rhopH3-loxP parasites 415 
following incubation with 5-ALA. In contrast, rapamycin-treatment had no 416 
effect on the capacity of the parental 1G5DC or DiCre-deficient RhopH3 NE 417 
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parasites to take up 5-ALA (Figure 6B-D). Combined, these results 418 
convincingly indicate that the PSAC/NPP is defective in the rhopH3 mutants. 419 
  420 
Discussion 421 
In this study we have shown that RhopH3 plays a central role in the 422 
formation of a functional RhopH complex and that mutation of RhopH3 423 
results in two severe, but very distinct, phenotypes: 1) a ~50% decrease in 424 
host erythrocyte invasion; and 2) a block in the development in the early 425 
trophozoite stage of those parasites that do invade. This block in 426 
development is a lethal event; no parasites carrying the mutant form of the 427 
rhopH3-loxP gene were recovered in a plaque assay and parasites with an 428 
intact rhopH3-loxP gene quickly outgrew the mutant parasites after 429 
rapamycin treatment. These results represent the first published evidence 430 
that RhopH3 is essential and mark the first time a rhoptry protein has been 431 
shown to have two separate, seemingly unrelated functions at different 432 
stages of the erythrocytic life cycle. RhopH3 is also the first rhoptry bulb 433 
protein to be directly assigned a role in invasion; other rhoptry proteins 434 
previously experimentally implicated in invasion are located in the rhoptry 435 
neck. The release of rhoptry neck proteins is considered the step at which 436 
the parasite commits to host cell entry (43), so the discovery of an 437 
important invasion factor that is presumably released later in the invasion 438 
pathway is important.  439 
Whilst it was surprising that loss of the function of the RhopH 440 
complex leads to two different, seemingly unrelated, phenotypes, previous 441 
results had hinted at a role for RhopH3 and the complex in both processes. 442 
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RhopH3, and proteolytic fragments of RhopH3, can bind to erythrocytes and 443 
to liposomes (44,45). This appears to occur even in the absence of other 444 
members of the RhopH complex, indicating that, for its role in invasion, 445 
RhopH3 may not require the function of the other proteins of the complex. 446 
Further supporting a role for RhopH3 in invasion is the finding that anti-447 
RhopH3 antibodies can block invasion (26,45). Nonetheless it is curious that 448 
~50% of the parasites still enter the erythrocyte in the absence of full-length 449 
RhopH3. RhopH3Δ4-6 may retain sufficient activity in 50% of the parasites to 450 
allow invasion to take place. Alternatively, these parasites could use a 451 
RhopH3-independent pathway. Invasion by P. falciparum relies on several 452 
redundant pathways and there is precedent for a partial reduction of 453 
invasion by mutant parasites (46). It will be of interest to determine 454 
whether invasion pathways that are currently thought to be redundant 455 
become essential in the absence of wild type RhopH3. A third possibility is 456 
that RhopH3 is involved in a post-invasion process. However, the invasion 457 
assay used here would detect all intracellular parasites that have completed 458 
invasion. We therefore favor the interpretation that the observed decrease 459 
in the number of newly invaded rhopH3-loxP parasites indicates that the 460 
invasion process is not completed in the mutants. 461 
 The other phenotype displayed by the RhopH3Δ4-6 mutants, the block 462 
in development during the early trophozoite stage, is likely the result of a 463 
defect in nutrient intake owing to improper trafficking ablating the function 464 
of RhopH1/Clag. The loss of sorbitol sensitivity of erythrocytes infected with 465 
the RhopH3Δ4-6 mutants and their impermeability to 5-ALA indicate that 466 
RhopH1/Clag3.1 (the RhopH1/Clag3 isotype expressed in these 3D7-derived 467 
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parasites) and RhopH1/Clag3.2 are not functioning at the erythrocyte 468 
surface. RhopH1/Clag3 proteins are transported to the erythrocyte surface 469 
in a PEXEL-independent manner (34) and are exposed on the surface of the 470 
erythrocyte (19), but the mechanism by which these proteins are 471 
transported from the rhoptry, beyond the PVM and to the erythrocyte 472 
plasma membrane is unknown. RhopH3 and RhopH2 are have been detected 473 
in the PVM immediately after invasion, (17)(47), as well as in the 474 
erythrocyte at later developmental stages of the intraerythrocytic parasite 475 
(34,48). It is likely that mislocalization of RhopH3Δ4-6 in merozoites 476 
prevents the proper, or properly timed, release of the complex during 477 
invasion and prevents RhopH1/Clag from being delivered to its correct 478 
location. As the RhopH1/Clag3.1 and RhopH1/Clag 3.2 in the trophozoite 479 
stage parasite derives entirely from protein that is introduced during 480 
invasion (15), mislocalization at the merozoite stage likely cannot be 481 
corrected by additional subsequent protein synthesis. 482 
 The complete arrest in development of the RhopH3Δ4-6 mutants in 483 
the cycle following gene modification (cycle 2) also provides insight into the 484 
potential roles of the RhopH1/Clag proteins. Little is known about these 485 
proteins other than the importance of the RhopH1/Clag3.1 and RhopH1/Clag 486 
3.2 proteins in the PSAC (18). However, chemical inhibition of 487 
RhopH1/Clag3.2 function and PSAC activity in parasites cultured in rich 488 
medium (RPMI 1640, the same medium used in this study) leads to only a 489 
small decrease in parasite viability (21). Similarly, parasites that do not 490 
produce RhopH1/Clag3.1 or RhopH1/Clag 3.2 have only a minimal growth 491 
disadvantage compared to wildtype parasites in a competition assay (13). 492 
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Parasites lacking RhopH1/Clag9 have no apparent growth phenotype in vitro 493 
(the gene is absent from the D10 and T9-96 laboratory strains that lack part 494 
of chromosome 9) (49,50). In contrast, parasites lacking RhopH1/Clag2 or 495 
RhopH1/Clag8 have not been reported so the essentiality of these proteins 496 
is unknown. We speculate that the RhopH3Δ4-6 mutants very likely transport 497 
none of the RhopH1/Clag proteins to the erythrocyte surface. If so, the 498 
observed growth phenotype is therefore essentially that of a disruption of 499 
all the clag genes. The striking growth phenotype of this mutant is in stark 500 
contrast to the mild phenotype of RhopH1/Clag3.2 inhibition (21) or the 501 
absence of both the RhopH1/Clag3 proteins (13) when the parasites are 502 
grown in RPMI. This may indicate that RhopH1/Clag2 and RhopH1/Clag8 play 503 
important roles in nutrient uptake as well, as previously suggested (21), and 504 
that RhopH complexes containing several different RhopH1/Clag proteins 505 
together mediate the uptake of the nutrients required for parasite growth in 506 
the infected erythrocyte. Interestingly, most Plasmodium species encode 507 
fewer RhopH1/Clag proteins than P. falciparum; some species possess only 508 
two clag genes, comprising a clag9 orthologue and a second orthologue more 509 
closely related to the other P. falciparum clag genes (3,10). In conclusion, 510 
our results raise the intriguing possibility that, in P. falciparum, 511 
RhopH1/Clag proteins in addition to RhopH1/Clag3.1 and RhopH1/Clag3.2 512 
function in nutrient import.  513 
 Together the results presented in this study provide new insights into 514 
the role of the rhoptry in the malarial blood stages and reveal that rhoptry 515 
proteins can function in multiple, distinct processes. They furthermore show 516 
that the functions of rhoptry proteins extend beyond the initial invasion of 517 
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the erythrocyte and can affect parasite growth throughout the blood stage 518 
life cycle.  519 
 520 
Materials and methods 521 
Reagents and antibodies, Oligonucleotide primers were from Sigma-Aldrich, 522 
as was rapamycin (cat# R0395), which was prepared as a 10 μM stock in 523 
DMSO. 5-aminoleuvlinic acid (5-ALA) from Sigma-Aldrich (cat# A3785) was 524 
prepared as a 1 mM stock in DMSO. Restriction enzymes were from New 525 
England Biolabs. The antifolate drug WR99120 (Jacobus Pharmaceuticals, 526 
New Jersey, USA), was stored as a 20 μM stock in DMSO. Polyclonal 527 
antiserum α-Ag44, which recognizes the C-terminal 134 amino acid residues 528 
of RhopH3 (30), was a kind gift of Ross Coppel (Monash University, 529 
Australia). A polyclonal antiserum against P. falciparum AMA1 has been 530 
previously described (51), as have polyclonal antibodies against P. 531 
falciparum MSP1 and the anti-MSP1 mAb 89.1 (52). Other antibodies were 532 
kindly provided by Osamu Kaneko, Nagasaki University Japan (rabbit anti-533 
RhopH1/Clag3.1A), John Vakonakis, University of Oxford UK (rabbit anti-534 
MAHRP1), Ross Coppel at Monash University Australia (anti-KAHRP), Tony 535 
Holder, the Francis Crick Institute UK (anti-RhopH2 mAb 61.3). Monoclonal 536 
antibody 7.7 (anti-EXP2) was from The European Malaria Reagent 537 
Repository, contributed by Jana McBride and the mouse anti-RAP2 mAb 538 
MRA-876 was obtained from BEI resources, National Institute of Allergy and 539 
Infectious Disease (NIAID), National Institutes of Health (NIH), contributed 540 
by Allan Saul. Use of these antibodies in immunoblot and IFA analyses have 541 
been described elsewhere (9,11,30,51,53-56).  542 
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 543 
P. falciparum culture, transfection and growth analysis. All P. falciparum 544 
transgenesis work described used the 3D7-derived DiCre-expressing clone 545 
1G5DiCre (27), here referred to as 1G5DC. Asexual blood stage parasites 546 
were continuously cultured in RPMI 1640 medium containing Albumax 547 
(Gibco) as a serum substitute and synchronised using established procedures 548 
(57). For introduction of transfection plasmids, mature schizonts were 549 
enriched using Percoll (GE Healthcare) and electroporated using an Amaxa 550 
4D electroporator and P3 Primary cell 4D Nucleofector X Kit L (Lonza) using 551 
programme FP158 as described (27).  552 
 Long-term parasite growth as measured by plaque-forming ability was 553 
determined by diluting trophozoite-stage cultures to a density of 10 554 
parasites per well in complete medium with human erythrocytes at a 555 
haematocrit of 0.75% and plating 200 μL of this suspension into flat 556 
bottomed 96 well microplates, as previously described (33). Plates were 557 
incubated for 10 days in gassed humidified sealed modular chambers before 558 
plaque formation was assessed by microscopic examination using a Nikon 559 
TMS inverted microscope (40x magnification) and documented using a 560 
Perfection V750 Pro scanner (Epson).    561 
 Growth characteristics of mutant parasites were determined by 562 
microscopy of Giemsa-stained thin films. Long-term growth was also 563 
measured using flow cytometry of hydroethidine-stained trophozoite-stage 564 
parasites, as described (58). Cultures adjusted to a parasitaemia of 0.1% 565 
were monitored every 48 h for up to 7 intraerythrocytic cycles. All 566 
experiments were carried out in triplicate, data analysed using GraphPad 567 
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Prism and presented as the mean ± standard error of the mean (SE). In 568 
addition, cells 92 h post-rapamycin treatment were fixed in 4% 569 
formaldehyde and 0.1% glutaraldehyde and stained with 2 μM Hoechst 33342 570 
(Invitrogen) before detection of the Hoechst emission (a measure of DNA 571 
replication) by the 355 nm laser of a LSR II (BD Biosciences), through a 572 
440/40 nm bandpass filter. Doublet cells were excluded using a FCS-A versus 573 
FCS-H display. Samples were analysed using FlowJo software.   574 
 Erythrocyte invasion assays were carried out using a modification of a 575 
method described previously (59). Highly synchronous, mature schizonts of 576 
the parasite clones under examination were enriched by centrifugation over 577 
Percoll cushions then added at a parasitaemia of 1% to fresh erythrocytes . 578 
After incubation for 4 h, parasites were stained with SYBR Green-I and the 579 
percentage of newly ring-infected erythrocytes was determined by flow 580 
cytometry using a BD FACS Calibur flow cytometer (BD Biosciences). SYBR 581 
Green-I was excited by a 488 nm 20 mW blue laser and detected by a 582 
530/30 filter. BD CellQuest Pro (BD Biosciences, UK) was used to collect 583 
100,000 events per sample. Experiments were done in triplicate, data 584 
analysed using GraphPad Prism and presented as the mean ± SE.  585 
 586 
Generation of rhopH3-loxP parasites and conditional RhopH3 truncation. 587 
Parasites harbouring a floxed segment of the genomic rhopH3 gene were 588 
generated by Cas9-mediated replacement of rhopH3 endogenous introns 3 589 
and 6 as well as the intervening sequence. The repair plasmid, called 590 
pESS_R3_E46_loxP (synthesised by GENEWIZ) comprised synthetic 591 
heterologous loxP-containing SERA2 and sub2 introns(29) flanking a 592 
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recodonized form of rhopH3 exons 4-6. The complete native sequences of 593 
exons 3 and 7 were included on either side of this central module to act as 594 
flanking regions for homology-directed repair. Protospacer Workbench(60) 595 
was used to identify 20 bp protospacer sequences specifically targeting 596 
rhopH3. To generate pSgRNA plasmids expressing suitable sgRNAs, InFusion-597 
based cloning (Clontech) was used to replace the BtgZI adaptor sequence of 598 
pL6-X(28) with annealed oligos encoding a sgRNA targeting rhopH3 exon 4 599 
(RHOPH3_sgRNA_E4_F and RHOPH3_sgRNA_E4_R, generating pSgRNA1), 5 600 
(RHOPH3_sgRNA_E5_F and RHOPH3_sgRNA_E5_R, generating pSgRNA2) or 6 601 
(RHOPH3_sgRNA_E6_F and RHOPH3_sgRNA_E6_R, generating pSgRNA3) (see 602 
Table 2 for sequences of all oligonucleotide primers used in this study). 603 
Schizonts of P. falciparum clone 1G5DC were transfected with 20 μg Cas9-604 
expressing pUF(28), 20 μg pESS_R3_E46_loxP repair plasmid and 8 μg of 605 
sgRNA-containing pSgRNA1, pSgRNA2 or pSgRNA3. Twenty-four hours post-606 
transfection, the electroporated parasites were treated with 2.5 nM 607 
WR99210 for 48 h to select for transfectants harbouring pUF1 before 608 
returning the cultures to medium without drug. Integrant parasites generally 609 
reached parasitaemia levels suitable for cryopreservation within 2-5 weeks. 610 
 Detection of integration of pESS_R3_E46_loxP in the parasite 611 
population was performed by diagnostic PCR using primers 612 
RHOPH3_exon2_F1 plus RHOPH3_exon5_WT_R (producing a product specific 613 
to the wild type rhopH3 locus), or RHOPH3_exon2_F1 plus RHOPH3_exon4-614 
6rec_R and RHOPH3_exon4-6rec_F plus RHOPH3_3UTR_R (producing 615 
products specific to the rhopH3-loxP modified locus). Integrant parasite 616 
clones rhopH3-loxP 5F5 and rhopH3-loxP 4B11 were then isolated by limiting 617 
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dilution. Persistence of the integrated DiCre locus in these clones was 618 
confirmed by PCR analysis using primers +27 plus -11 producing a 1900 bp 619 
product specific to the integrated DiCre cassette in 1G5DC parasites, or +27 620 
plus -25 producing an amplicon of 1700 bp specific to the unmodified SERA5 621 
locus. 622 
 Recombination between the loxP sites was induced in tightly 623 
synchronised ring-stages of parasite clones rhopH3-loxP 5F5 and rhopH3-624 
loxP 4B11 by incubation for 4 h in the presence of 100 nM rapamycin in 1% 625 
(v/v) DMSO; mock treatment was with 1% (v/v) DMSO only (vehicle control). 626 
DiCre-mediated excision of the floxed rhopH3 exons 4-6 was detected by 627 
PCR analysis of schizont stage genomic DNA (harvested ~40 h following mock 628 
or rapamycin treatment) using primers RHOPH3_exon2_F1 and 629 
RHOPH3_exon7_R. Truncation of RhopH3 was evaluated by immunoblot 630 
analysis of SDS extracts of mature Percoll-enriched schizonts, probing with 631 
anti-Ag44 antibodies (or anti-AMA1 as a loading control) followed by 632 
horseradish-peroxidase secondary antibodies as described(61).  633 
 634 
Southern blot. For Southern blot analysis, a 738 bp probe corresponding to 635 
part of rhopH3 exon 3 was produced by PCR amplification from P. 636 
falciparum IG5DC genomic DNA with primers RHOPH3_exon3_SB_F and 637 
RHOPH3_exon3_SB_R (Table 2). Probe radiolabelling and hybridisation to 638 
SacI/BsgI/XmnI-digested gDNA from clones of interest was as previously 639 
described (62).  640 
 641 
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Immunoprecipitation and immunoblot analysis. For analysis of RhopH 642 
complex formation, mature Percoll-enriched schizont-stage parasites (42 h 643 
post rapamycin or mock treatment) were harvested and stored at -80˚C. 644 
Frozen parasite pellets were thawed into 100 μL NP-40 lysis buffer (1% 645 
Nonidet P-40, 150 mM NaCl, 50 mM Tris-HCL, 5 mM EDTA, 5 mM EGTA pH 646 
8.0) containing a complete protease inhibitor cocktail (Roche). Samples 647 
were clarified by centrifugation at 14,000 rpm at 4˚C and the supernatant 648 
passed through a 0.22 μm cellulose acetate Spin-X centrifuge tube filter 649 
(Corning). 100 μL Protein G-Sepharose beads (Abcam) were added to the 650 
resulting supernatant and pre-clearing carried out at 4oC overnight. 651 
Following addition of mAb 61.3 (9), samples were incubated at 4oC overnight 652 
before antigen-antibody complexes were precipitated using Protein G-653 
Sepharose beads overnight at 4˚C. The beads were washed five times in 654 
wash buffer I (50 mM Tris-HCl pH 8.2, 5 mM EDTA, 0.5% Nonidet P-40, 1 655 
mg/mL bovine serum albumin, 0.5 M NaCl) and twice in wash buffer II (50 656 
mM Tris-HCl pH 8.2, 5 mM EDTA, 0.5% Nonidet P-40) before antigen-antibody 657 
complexes were eluted using NuPAGE LDS Sample Buffer (Life Technologies) 658 
and proteins resolved using precast NuPAGE Novex 3-8% Tris-Acetate protein 659 
gels (Life Technologies). Following electrophoresis, samples were evaluated 660 
by immunoblot analysis probing with anti-Ag44 or anti-RhopH1/Clag3.1A 661 
antibodies followed by horseradish-peroxidase secondary antibodies as 662 
described (61). 663 
 664 
Immunofluorescence microscopy. Immunofluorescence microscopy was 665 
performed on formaldehyde-fixed thin blood smears, permeabilised with 666 
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0.1% (v/v) Triton X-100. Monoclonal anti-RAP2 (MRA-876), directly labeled 667 
with Alexa Fluor 594 using the Alexa Fluor 594 Antibody Labelling Kit (Life 668 
Technologies), was used at a dilution of 1:300. Samples were probed with 669 
primary antibodies used at the following dilutions: anti-Ag44 (1:2000), mAb 670 
61.3 (1:100), anti-CL3.1A (1:100), anti-MAHRPI (1:2000), anti-KAHRP 671 
(1:250), rabbit anti-MSP1 (1:1000), mAb 89.1 (1:1000), and mAb 7.7 (1:100). 672 
Bound primary antibodies were detected using Alexa Fluor 488-, 566- or 594-673 
conjugated anti-rabbit or anti-mouse secondary antibodies (Life 674 
Technologies), diluted 1:8000. Slides were mounted in ProLong Gold 675 
Antifade Mountant with DAPI (Life Technologies) and trophozoite images 676 
captured using a Nikon Eclipse Ni-E widefield microscope with a 677 
100x/1.45NA objective and a Hamamatsu C11440 digital camera. Schizont 678 
stage images were captured with a Zeiss LSM 880 using a 63x/1.4 NA 679 
objective equipped with an Airyscan detector to improve the optical 680 
resolution of the scanned images. The DAPI, Alexa Fluor 488 and Alexa Fluor 681 
594 channels were imaged sequentially over the axial dimension and 682 
processed using the integrated Zeiss software to enhance the optical 683 
resolution isometrically ~1.8 fold. All images were processed using either 684 
the Zen 2012 or FIJI software packages. For display purposes, linear 685 
adjustments were made to the intensity scale of each channel to equalize 686 
the intensity output to enhance areas of co-localization. Relative intensities 687 
between samples are not comparable. 688 
 689 
Transmission electron microscopy. Parasite cultures 92 h following 690 
rapamycin (or mock) treatment were fixed at 37ºC in 8% formaldehyde in 691 
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0.2 M phosphate buffer pH 7.4 (PB) for 15 min by adding 1 volume of 692 
fixative solution to 1 volume of culture. The cells were pelleted, then 693 
further incubated in 2.5% glutaraldehyde, 4% formaldehyde in 0.1 M PB at 694 
room temperature for a further 30 min. Cells were washed in 0.1 M PB 695 
before being embedded in 4% (w/v) low-melting point agarose in distilled 696 
water. The agarose-embedded samples were cut into 1 mm3 blocks, post-697 
fixed in 1% (w/v) OsO4 and 1.5% (w/v) potassium ferrocyanide for 60 min at 698 
4ºC then incubated sequentially in 1% (w/v) tannic acid in 0.05 M PB for 45 699 
min and 1% (w/v) sodium sulphate in 0.05 M PB for 5 min. The samples were 700 
washed in water and dehydrated through a graded series of ethanol before 701 
being embedded in Epon resin (Taab 812). Blocks were trimmed and 702 
ultrathin 70 nm sections cut using a diamond knife on a UC6 Ultramicrotome 703 
(Leica Microsystems), picked up on 150 hexagonal mesh copper grids and 704 
post stained with lead citrate before being imaged using a Tecnai G2 Spirit 705 
120 kV transmission electron microscope (FEI Company) with an Orius 706 
camera (Gatan Inc.). 707 
    708 
Analysis of erythrocyte membrane permeability. Sorbitol sensitivity of 709 
parasites was determined 72 h following rapamycin or DMSO treatment (i.e. 710 
in cycle 2). Cultures at equal parasitaemia were incubated in osmotic lysis 711 
buffer (280 mM sorbitol, 20 mM Na-HEPES, 0.1 mg/mL BSA, pH 7.4) for 7 712 
min, then hemoglobin release determined by measuring the absorbance of 713 
the cell supernatants at 405 nm, as previously described(63,64).  714 
 5-ALA uptake was determined by incubating cultures of synchronous 715 
cycle 2 ring-stage parasites overnight in phenol red-free RPMI 1640 medium 716 
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(K-D Medical) supplemented with 200 μM 5-ALA. Just prior to analysis, 717 
parasite nuclei were stained by treatment with 2 μM Hoechst. PPIX and 718 
Hoechst fluorescence were captured using a Zeiss LSM 880 equipped with a 719 
63x/1.4 NA objective in standard confocal detection mode. Images were 720 
captured with the same acquisition setting so that measurements of 721 
intensity are directly comparable. Co-occurrence of PPIX and Hoechst was 722 
quantified using the MetaMorph software “Cell Scoring” application. Cells 723 
were also analyzed on a SORP LSRFortessa, detecting PPIX emission with a 724 
532 nm laser through a 605/40 nm bandpass filter and Hoechst emission 725 
with the 406 nm laser through a 440/40 nm bandpass filter. Erythrocyte 726 
doublets were excluded using a FCS-A versus FCS-H display and data 727 
analyzed by BD FACSDiva software.   728 
 729 
Time-lapse video microscopy. P. falciparum egress was imaged as 730 
previously described (27,65), using 1 μM (4-[7-[(dimethylamino)methyl]-2-(4-731 
fluorphenyl)imidazo[1,2-α]pyridine-3-yl]pyrimidin-2-amine (compound 2) to 732 
tightly synchronise egress. Following removal of compound 2 by washing, 733 
parasites were suspended in fresh pre-warmed medium and introduced into 734 
a pre-warmed microscopy chamber on a temperature controlled microscope 735 
stage at 37oC. Beginning 6 min after washing off the compound 2, DIC 736 
images were collected at 5 s intervals for 30 min using a Nikon Eclipse Ni 737 
Microscope fitted with a Hamamatsu C11440 digital camera and converted 738 
to QuickTime movies using Nikon NIS-Elements software.   739 
  740 
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 1058 
Table 1. Conditional truncation of RhopH3 results in decreased parasite 1059 
survival as determined by plaque assay.  1060 
 1061 
a Plaque 
assay no. Treatment 
b Proportion of wells 
containing plaques (%) 
Mean number of 
plaques/well 
1 
(clone 5F5) 
  
DMSO 98.88 7.7 
Rapamycin 10.56 0.11 
2 
(clone 5F5) 
  
DMSO 100 9.1 
Rapamycin 8.89 0.09 
3 
(clone 4B11) 
  
DMSO 99.44 5.24 
Rapamycin 9.44 0.1 
 1062 
a Three independent plaque assays were set up on different days. 1063 
b A total of 180 wells were used for each treatment (+/-RAP) in each assay. 1064 
 1065 
 1066 
 1067 
  1068 
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 1069 
 1070 
 1071 
Table 2. Oligonucleotide primers used in this study. Guide sequences 1072 
shown in bold. 1073 
 1074 
Primer name Sequence (5’-3’)
RHOPH3_sgRNA_E4_F* taagtatataatattTTCTTCGTTTTTAAAAAAAGgttttagagctagaa 
RHOPH3_sgRNA_E4_R* ttctagctctaaaacCTTTTTTTAAAAACGAAGAAaatattatatactta 
RHOPH3_sgRNA_E5_F* taagtatataatattCACCGATTTTAGCTTTAAAGgttttagagctagaa 
RHOPH3_sgRNA_E5_R* ttctagctctaaaacCTTTAAAGCTAAAATCGGTGaatattatatactta 
RHOPH3_sgRNA_E6_F* taagtatataatattACATTCTTATCATTATATTTgttttagagctagaa 
RHOPH3_sgRNA_E6_R* ttctagctctaaaacACATTCTTATCATTATATTTaatattatatactta 
RHOPH3_exon2_F1 AGGAAATGGCCCAGACGC
RHOPH3_exon5_WT_R TCTTTAAAGCTAAAATCGGTGATATTATGGCTC
RHOPH3_exon4-6rec_R CAGGAAGTTACCTTTCAGCAGGG
RHOPH3_exon4-6rec_F CCCTGCTGAAAGGTAACTTCCTG
RHOPH3_3UTR_R CGAATATGTAATCAGTTGTATTTTTTCTCTAAAAGTTCATAG 
+27 CAATATCATTTGAATCAAACAGTGGT
-11 CTTTGCCATCCAGGCTGTTC
-25 CCATTGGACTAGAACCTTCAT
RHOPH3_exon7_R CATAAAGAACGTCTTGTTTTCTGTATCCAATACC
RHOPH3_exon3_SB_F CAAATATGCTATATGTGTAGGTACTCAATTTAAC
RHOPH3_exon3_SB_R CATATAACTTTGGAGATGTAGAACCACAAGG
  1075 
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Figure legends 1076 
Figure 1 Conditional truncation of the rhopH3 gene. A) The rhopH3 gene 1077 
comprises seven exons (numbered grey boxes) and six introns (blue lines). 1078 
Using Cas9-mediated recombination, the region spanning introns 3 through 6 1079 
was replaced with two loxP-containing (purple open arrowhead) P. 1080 
falciparum introns (SERA2 (orange line) and sub2 (green line)) flanking a 1081 
recodonized and fused version of exons 4 through 6 (exon 4-6, green box). 1082 
Integration of this sequence by homologous recombination was promoted by 1083 
the addition sequences of exon 3 and 7 to either side of the introns. Colored 1084 
arrowheads, primer binding sites. B, S and X, BsgI, SacI and XmnI restriction 1085 
sites. Dotted line, probe used for Southern blotting. Rapamycin-induced 1086 
site-specific recombination between the loxP sites removes the recodonized 1087 
exon 4-6. B) PCR analysis of rhopH3-loxP clones 5F5 and 4B11 confirms the 1088 
expected gene modification event. Genomic DNA from parental 1G5DC (WT) 1089 
parasites or the clones was used as template for PCR using the indicated 1090 
primers (see panel A). Numbers between the arrowheads indicate the 1091 
expected size of the amplicon. C) Southern blot analysis of parental 1G5DC 1092 
(WT) and the rhopH3-loxP parasite clones confirms the expected 1093 
modification of the rhopH3 locus. Genomic DNA was digested with BsgI, SacI 1094 
and XmnI and hybridized with a radiolabeled probe that binds to part of 1095 
exon 3 (dotted line in panel A). Expected fragment sizes are 3016 bp for the 1096 
WT rhopH3 locus and 3349 bp for the rhopH3-loxP locus.  D) Efficient 1097 
rapamycin-induced truncation of the rhopH3 gene. Clones rhopH3-loxP 5F5 1098 
and 4B11 were analyzed by PCR ~44 h after treatment with DMSO (D) or 1099 
rapamycin (R) using the indicated primers (see panel A). Excision decreases 1100 
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the amplicon from 2760 bp to 1755 bp. E) Southern blot showing efficient 1101 
rapamycin-induced truncation of the rhopH3 gene. Genomic DNA extracted 1102 
from control or rapamycin-treated rhopH3-loxP clones 5F5 and 4B11 was 1103 
digested and probed as described in panel C. Expected fragment sizes are 1104 
3349 bp for the non-excised locus and 4784 bp for the excised locus. F) 1105 
Immunoblot analysis of mature schizonts of rhopH3-loxP clone 5F5, 1106 
examined ~44 h following treatment at ring stage with DMSO (D) or 1107 
rapamycin (R). The blots were probed with an antibody against RhopH3 (left 1108 
panel) or the merozoite protein AMA1 (right panel) as a loading control. The 1109 
expected molecular masses of WT RhopH3 and RhopH3Δ4-6 are 110 kDa and 1110 
~70 kDa, respectively. In panels B-F, positions of relevant molecular mass 1111 
markers are indicated.  1112 
 1113 
Figure 2 Truncation of RhopH3 leads to mistrafficking of components of the 1114 
RhopH complex and loss of complex formation. A) IFA showing colocalization 1115 
of RhopH3, RhopH2 and RhopH1/Clag3.1 with the rhoptry marker RAP2 in 1116 
schizonts of control (DMSO) rhopH3-loxP parasites but loss of colocalization 1117 
following rapamycin (Rapa) treatment. Parasite nuclei were visualized by 1118 
staining with 4,6-diamidino-2-phenylindole (DAPI). Scale bar, 5 μm. B) 1119 
Colocalization of the members of the RhopH complex. RhopH3, RhopH2 and 1120 
RhopH1/Clag3.1 colocalize in rhopH3-loxP parasites treated with DMSO, but 1121 
this colocalization is lost in parasites treated with rapamycin. C) 1122 
Mislocalisation and reduced levels of RhopH3 in naturally released free 1123 
merozoites of rhopH3-loxP parasites treated with rapamycin. Samples were 1124 
probed with a monoclonal antibody to the merozoite surface marker MSP1 1125 
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as well as anti-RhopH3 antibodies. Scale bar, 2 μm D) Immunoprecipitation 1126 
reveals disruption of the RhopH complex in rapamycin-treated rhopH3-loxP 1127 
parasites. RhopH2 was immunoprecipitated from extracts of control or 1128 
rapamycin-treated rhopH3-loxP parasites. Subsequent immunoblotting with 1129 
antibodies against RhopH3 or RhopH1/Clag3.1 revealed the absence of 1130 
RhopH3 from the immunoprecipitates derived from the rapamycin-treated 1131 
parasites, although RhopH2 and RhopH1/Clag3.1 still showed association. 1132 
Arrowheads indicate the expected position of migration of the full-length 1133 
(WT) and truncated RhopH3, and RhopH1/Clag3.1. The rhoph3-loxP clone 1134 
5F5 was used throughout for these experiments. 1135 
 1136 
Figure 3 Loss of long-term viability in parasites lacking the RhopH complex. 1137 
A) Representative wells seeded with identical concentrations (10 parasitised 1138 
cells/well) of DMSO-treated or rapamycin-treated rhopH3-loxP clone 5F5 1139 
parasites, showing formation of plaques only in the wells seeded with DMSO-1140 
treated parasites. Two of the plaques are indicated by white arrowheads. B) 1141 
PCR analysis of the rhopH3-loxP locus in the small number of clones isolated 1142 
from wells seeded with rapamycin-treated rhopH3-loxP parasites. The size 1143 
of the PCR product indicates excision of the floxed sequence had not taken 1144 
place in these seven clones (numbered 1-7), whereas rapamycin induced 1145 
efficient excision in the parent 5F5 clone  (left-hand two tracks). For PCR 1146 
strategy, see Figure 1D. C) PCR analysis of the modified SERA5 locus in 1147 
parasite clone RhopH3 NE, showing loss of the DiCre cassette in this clone. 1148 
D) Growth curves showing replication of parasites of the indicated clones 1149 
over the course of 5 erythrocytic cycles. Data were averaged from 3 1150 
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biological replicate experiments and presented as the mean ± standard error 1151 
of the mean. E) Non-excised parasites quickly outgrow RhopH3Δ4-6 1152 
parasites. The relative abundance of parasites harboring the excised or 1153 
intact rhopH3-loxP locus in a population of rapamycin-treated rhopH3-loxP 1154 
clone 5F5 parasites was determined by diagnostic PCR over the course of 7 1155 
erythrocytic growth cycles (indicated, where cycle 1 indicates that in which 1156 
treatment occurred). F) Decreased erythrocyte invasion by rapamycin-1157 
treated rhopH3-loxP parasites. Parasites of the indicated clones were 1158 
treated with DMSO or rapamycin and allowed to invade fresh erythrocytes. 1159 
Ring-stage parasitemia levels were determined 4 h later. Data were 1160 
averaged from 3 biological replicate experiments. Error bars depict standard 1161 
error of the mean. Statistical significance was determined by a two-tailed t-1162 
test where p≤0.0001 (indicated by asterisks) and p>0.05, non-significant 1163 
(ns). 1164 
 1165 
Figure 4 Loss of the RhopH complex results in developmental arrest. A) 1166 
Developmental block in rapamycin-treated rhopH3-loxP parasites. Giemsa-1167 
stained images showing intracellular development of DMSO-treated and 1168 
rapamycin-treated rhopH3-loxP clone 5F5 parasites from the end of cycle 1 1169 
to the end of cycle 2. A clear developmental block was evident in the 1170 
rapamycin-treated parasites in cycle 2. The number of hours following the 1171 
beginning of cycle 1 is indicated, as well as its relation to the time point of 1172 
rapamycin treatment (indicated in the schematic timeline). B) Flow 1173 
cytometry analysis of DMSO-treated and rapamycin-treated rhopH3-loxP 1174 
clones 5F5 and 4B11. Analysis was performed at the end of the cycle 2 (92 h 1175 
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after rapamycin-treatment). The intensity of Hoechst 33342 staining 1176 
provides a measure of the DNA content of the parasites, reflecting parasite 1177 
development.  1178 
 1179 
Figure 5 Loss of the RhopH complex does not ablate parasite protein export. 1180 
Cycle 2 (72 h post rapamycin treatment) DMSO-treated and rapamycin-1181 
treated rhopH3-loxP clone 5F5 trophozoite-stage parasites were probed with 1182 
antibodies against the parasitophorous vacuole membrane marker EXP2 to 1183 
delineate the parasite in the infected erythrocyte, as well as antibodies 1184 
specific for either the Maurer’s cleft marker MAHRP1 (top panels) or the 1185 
export marker KAHRP (bottom panels). Scale bar, 5 μm. B) Transmission 1186 
electron micrograph showing a comparison between cycle 2 parasites of 1187 
DMSO-treated or rapamycin-treated rhopH3-loxP clone 5F5 parasites ~ 92 h 1188 
following rapamycin treatment. The developmental block in the RhopH3Δ4-6 1189 
parasite is clearly evident, as is the presence of knobs (arrowed) on the 1190 
surface of the erythrocyte in both cases. Components of the mutant parasite 1191 
labelled are the digestive vacuole (DV), haemozoin (H), nucleus (N), 1192 
parasitophorous vacuole membrane (PVM), cytostomes (C) and parasite 1193 
plasma membrane (PPM). The mutant parasites displayed no obvious 1194 
ultrastructural differences from wild-type trophozoites at a similar 1195 
developmental stage (not shown). Scale bar, 1 μm  1196 
 1197 
Figure 6 Loss of the RhopH complex results in reduced sorbitol sensitivity 1198 
and reduced uptake of exogenous small molecules. A) Synchronous cycle 2 1199 
parasites of the indicated clone (parasitaemia ~5%) treated 72 h previously 1200 
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with DMSO or rapamycin in cycle 1 were suspended in osmotic lysis buffer 1201 
containing 280 mM sorbitol or in PBS, and the resulting cell lysis determined 1202 
by measuring the absorbance of the supernatant at 405 nm. An equal 1203 
volume of parasite culture was lysed in 0.15% (w/v) saponin to give a value 1204 
for 100% lysis and all other absorbance values normalized to this. Data were 1205 
averaged from 3 biological replicate experiments. Statistical significance 1206 
was determined by a two-tailed t-test; significance levels are indicated: 1207 
p≤0.001, ***; p≤0.01, **; p≤0.05, *; and p>0.05, non-significant (ns). B) 1208 
Uptake of 5-ALA by erythrocytes infected with either DMSO-treated or 1209 
rapamycin-treated rhopH3-loxP clone 5F5 parasites at cycle 2. Cultures 1210 
were incubated overnight with 200 μM 5-ALA and uptake of the compound 1211 
and its subsequent conversation to PPIX in infected erythrocytes visualized 1212 
by fluorescence microscopy. Infected erythrocytes were visualized by 1213 
staining with Hoechst 33342. Top panels show fields of view containing 1214 
multiple infected erythrocytes of the indicated strain. Scale bar, 50 μm 1215 
Bottom panels show individual infected erythrocytes. Scale bar, 5 μm. C) 1216 
Quantitation of the levels of uptake of 5-ALA by infected erythrocytes. For 1217 
each condition, a total of 1300 Hoechst-positive cells were analyzed for 1218 
intensity of PPIX fluorescence using MetaMorph (Molecular Devices) and a 1219 
statistical significance was determined by a two-tailed t-test. Significance 1220 
levels are indicated: p≤0.0001, **** and p>0.05, non-significant (ns). D) FACS 1221 
analysis of 5-ALA-treated parasites. Uptake of 5-ALA and its subsequent 1222 
conversation to PPIX in cycle 2 parasites following treatment in cycle 1 with 1223 
rapamycin or DMSO was determined by flow cytometry of Hoechst stained 1224 
parasites. Gating was applied to distinguish Hoechst negative cells (red 1225 
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population), Hoechst positive/PPIX negative cells (green population) and 1226 
Hoechst positive/PPIX-positive cells (purple population). For the 1G5DC 1227 
parental and RhopH3-loxP NE parasite clones, most of the parasites were 1228 
positive for both Hoechst and PPIX fluorescence regardless of their 1229 
treatment with rapamycin or DMSO. In contrast, for rapamycin-treated 1230 
rhopH3-loxP clones 5F5 and 4B11, most of the parasites were Hoechst 1231 
positive/PPIX negative indicating a defect in 5-ALA uptake.   1232 
 1233 
 1234 
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Supplemental figure legends. 1236 
 1237 
Figure 1 – figure supplement 1.Multiple alignment of predicted primary 1238 
sequences of rhopH3 orthologues from P. falciparum (PF3D7_0905400), P. 1239 
chabaudi (PCHAS_0416900) and P. vivax (PVX_098712). The portion of the 1240 
protein encoded by exon 4-6 in the P. falciparum orthologue is underlined. 1241 
Note that this region includes some of the most highly conserved regions of 1242 
the protein. Sequence data were obtained from PlasmoDB (1) and aligned 1243 
using Clustal Omega (2). ‘*’indicates positions of identity, ‘:’ indicates 1244 
conservation of residues with strongly similar chemical properties  and ‘.’ 1245 
indicates conservation of residues of weakly similar properties. 1246 
 1247 
Figure 1 – figure supplement 2. Modification (floxing) of the rhoph3 gene 1248 
does not impact on gene expression or parasite growth. A) Immunoblot 1249 
analysis of untreated mature schizonts of rhopH3-loxP clones 5F5 and 4B11, 1250 
as well as the RhopH3 NE clone and the parental 1G5DC parasites. The blots 1251 
were probed with an antibody against RhopH3 (top), RhopH1/Clag3.1 1252 
(middle) or the merozoite protein EBA175 (3) (bottom) as a loading control. 1253 
B) Growth curves showing similar replication rates of parasites of the 1254 
indicated clones (not treated with rapamycin) over the course of 4 1255 
erythrocytic cycles. Data were averaged from 3 biological replicate 1256 
experiments and presented as the mean ± standard error of the mean. 1257 
Linear regression analysis showed that all the slopes fall within the same 1258 
95% confidence interval range. 1259 
 1260 
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Figure 1 – figure supplement 3. Conditional truncation of RhopH3 in both 1261 
the 5F5 and 4B11 rhopH3-loxP clones. Immunoblot analysis of mature 1262 
schizonts of the indicated clones ~44 h following treatment at ring stage 1263 
with DMSO (D) or rapamycin (R). The blots were probed with an antibody 1264 
against RhopH3 (top) or the mAb 89.1 against the merozoite surface protein 1265 
MSP1 (bottom) as a loading control. The expected molecular masses of WT 1266 
RhopH3 and RhopH3Δ4-6 are 110 kDa and ~70 kDa, respectively. Positions of 1267 
relevant molecular mass markers are indicated. 1268 
 1269 
Figure 2 – figure supplement 1. Truncation of RhopH3 leads to 1270 
mistrafficking of components of the RhopH complex. IFA of mature schizonts 1271 
of control (DMSO) and rapamycin-treated rhopH3-loxP parasites, probed 1272 
with MSP1-specific antibodies (either mAb 89.1 or rabbit polyclonal anti-1273 
MSP1 antibodies; red) and antibodies to the three indicated RhopH 1274 
components (green). Mis-localisation of the RhopH proteins was observed in 1275 
all cases, and in the case of RhopH3 the protein often appeared to reside 1276 
external to the plasma membrane of intracellular merozoites. Parasite 1277 
nuclei were visualized by staining with DAPI. Note that, for clarity, the 1278 
merge panels do not include the DAPI signal. Scale bar, 5 μm. 1279 
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Supplementary Video 1 Parasite egress is unaffected by loss of the RhopH 1298 
complex. Synchronized parasites of rhopH3-loxP clone 4B11 were treated 1299 
with DMSO or rapamycin at ring stage, then allowed to mature to schizont 1300 
stage and further synchronised by incubation for 3-5 h in the presence of 1 1301 
μM (4-[7-[(dimethylamino)methyl]-2-(4-fluorphenyl)imidazo[1,2-α]pyridine-1302 
3-yl]pyrimidin-2-amine (compound 2), which reversibly stalls egress. Egress 1303 
of the parasites was then monitored by time-lapse DIC video microscopy 1304 
following removal of the compound 2, as described previously1. DMSO-1305 
treated samples are shown on the left, rapamycin-treated are samples 1306 
shown on the right. 1307 
 1308 
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